表紙
市場調查報告書
商品編碼
1043193

患者腫瘤組織移植的全球市場(2021年∼2025年)

Global Patient Derived Xenograft Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球患者腫瘤組織移植的市場規模在2021年∼2025年的預測期間內,預計將以16.66%的年複合成長率擴大,並成長到1億8,819萬美元。市場成長的主要因素有對個人化醫療的需求提升,以及免疫功能低下大鼠的開發等。

本報告提供患者腫瘤組織移植的世界市場調查,提供市場規模和預測,市場促進因素及課題,市場趨勢,各用途,各地區的市場分析,業者情勢,主要供應商分析等系統性資訊。

目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模(2020年)
  • 市場規模預測(2020年∼2025年)

波特的五力分析

  • 五力的摘要
  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

各用途的市場區隔

  • 市場區隔
  • 各用途的比較
  • 前臨床醫藥品開發
  • 生物標記分析
  • 各用途的市場機會

客戶形勢

  • 客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 各地區形勢的市場機會
  • 推動市場要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 阻礙的形勢

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Champions Oncology Inc.
  • Charles River Laboratories International Inc.
  • Experimental Pharmacology and Oncology EPO Berlin Buch GmbH
  • Hera Biolabs Inc.
  • Oncodesign SA
  • PerkinElmer Inc.
  • Pharmatest Services Oy
  • The Jackson Laboratory
  • UROSPHERE SAS
  • WuXi AppTec Co. Ltd.

附錄

目錄
Product Code: IRTNTR71179

Technavio has been monitoring the patient derived xenograft market and it is poised to grow by $ 188.19 million during 2021-2025, progressing at a CAGR of 16.66% during the forecast period. Our report on the patient derived xenograft market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing demand for personalized medicine and the development of immunodeficient rats. In addition, the growing demand for personalized medicine is anticipated to boost the growth of the market as well.

The patient derived xenograft market analysis includes the application segment and geographic landscape.

Technavio's patient derived xenograft market is segmented as below:

By Application

  • Preclinical drug development
  • Bio marker analysis

By Geographic

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increasing incidence of lung cancersas one of the prime reasons driving the patient derived xenograft market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on patient derived xenograft market covers the following areas:

  • Patient derived xenograft market sizing
  • Patient derived xenograft market forecast
  • Patient derived xenograft market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading patient derived xenograft market vendors that include Champions Oncology Inc., Charles River Laboratories International Inc., Experimental Pharmacology and Oncology EPO Berlin Buch GmbH, Hera Biolabs Inc., Oncodesign SA, PerkinElmer Inc., Pharmatest Services Oy, The Jackson Laboratory, UROSPHERE SAS, and WuXi AppTec Co. Ltd. Also, the patient derived xenograft market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Application
    • Market segments
    • Comparison by Application
    • Preclinical drug development - Market size and forecast 2020-2025
    • Bio marker analysis - Market size and forecast 2020-2025
    • Market opportunity by Application
  • Customer landscape
    • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Champions Oncology Inc.
    • Charles River Laboratories International Inc.
    • Experimental Pharmacology and Oncology EPO Berlin Buch GmbH
    • Hera Biolabs Inc.
    • Oncodesign SA
    • PerkinElmer Inc.
    • Pharmatest Services Oy
    • The Jackson Laboratory
    • UROSPHERE SAS
    • WuXi AppTec Co. Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Application - Market share 2020-2025 (%)
  • 22: Comparison by Application
  • 23: Preclinical drug development - Market size and forecast 2020-2025 ($ million)
  • 24: Preclinical drug development - Year-over-year growth 2020-2025 (%)
  • 25: Bio marker analysis - Market size and forecast 2020-2025 ($ million)
  • 26: Bio marker analysis - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Application
  • 28: Customer landscape
  • 29: Market share By Geographical Landscape 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity By Geographical Landscape ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Champions Oncology Inc. - Overview
  • 48: Champions Oncology Inc. - Business segments
  • 49: Champions Oncology Inc. - Key offerings
  • 50: Champions Oncology Inc. - Key customers
  • 51: Champions Oncology Inc. - Segment focus
  • 52: Charles River Laboratories International Inc. - Overview
  • 53: Charles River Laboratories International Inc. - Business segments
  • 54: Charles River Laboratories International Inc. - Key offerings
  • 55: Charles River Laboratories International Inc. - Key customers
  • 56: Charles River Laboratories International Inc. - Segment focus
  • 57: Experimental Pharmacology and Oncology EPO Berlin Buch GmbH - Overview
  • 58: Experimental Pharmacology and Oncology EPO Berlin Buch GmbH - Product and service
  • 59: Experimental Pharmacology and Oncology EPO Berlin Buch GmbH - Key offerings
  • 60: Experimental Pharmacology and Oncology EPO Berlin Buch GmbH - Key customers
  • 61: Experimental Pharmacology and Oncology EPO Berlin Buch GmbH - Segment focus
  • 62: Hera Biolabs Inc. - Overview
  • 63: Hera Biolabs Inc. - Product and service
  • 64: Hera Biolabs Inc. - Key offerings
  • 65: Hera Biolabs Inc. - Key customers
  • 66: Hera Biolabs Inc. - Segment focus
  • 67: Oncodesign SA - Overview
  • 68: Oncodesign SA - Product and service
  • 69: Oncodesign SA - Key offerings
  • 70: Oncodesign SA - Key customers
  • 71: Oncodesign SA - Segment focus
  • 72: PerkinElmer Inc. - Overview
  • 73: PerkinElmer Inc. - Business segments
  • 74: PerkinElmer Inc. - Key offerings
  • 75: PerkinElmer Inc. - Key customers
  • 76: PerkinElmer Inc. - Segment focus
  • 77: Pharmatest Services Oy- Overview
  • 78: Pharmatest Services Oy- Product and service
  • 79: Pharmatest Services Oy- Key offerings
  • 80: Pharmatest Services Oy- Key customers
  • 81: Pharmatest Services Oy- Segment focus
  • 82: The Jackson Laboratory - Overview
  • 83: The Jackson Laboratory - Business segments
  • 84: The Jackson Laboratory - Key offerings
  • 85: The Jackson Laboratory - Key customers
  • 86: The Jackson Laboratory - Segment focus
  • 87: UROSPHERE SAS - Overview
  • 88: UROSPHERE SAS - Product and service
  • 89: UROSPHERE SAS - Key offerings
  • 90: UROSPHERE SAS - Key customers
  • 91: UROSPHERE SAS - Segment focus
  • 92: WuXi AppTec Co. Ltd. - Overview
  • 93: WuXi AppTec Co. Ltd. - Business segments
  • 94: WuXi AppTec Co. Ltd. - Key offerings
  • 95: WuXi AppTec Co. Ltd. - Key customers
  • 96: WuXi AppTec Co. Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations